New weekly shot could replace IV drips for nerve disease
NCT ID NCT07540221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a weekly under-the-skin antibody treatment (XEMBIFY) provides similar blood levels as a standard IV infusion (Gamunex-C) given every 3 weeks in people with CIDP, a chronic nerve disorder. About 40 adults who are stable on IVIG will first receive Gamunex-C for 19 weeks, then switch to XEMBIFY for 16 weeks. The goal is to see if the weekly shot can match the IV treatment in maintaining antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Immune globulin (antibodies) given as XEMBIFY under the skin or Gamunex-C into a vein
What this could lead to
If successful, this could show that a weekly under-skin shot works as well as a once-every-3-weeks IV infusion for managing CIDP, offering more convenience.
What could go wrong
This is a small, early-phase study focused on drug levels, not on whether symptoms improve. It may not prove that XEMBIFY controls CIDP long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIDP (CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GC2402 Study Site 104
RECRUITINGRancho Mirage, California, 92270, United States
Contact Email: •••••@•••••
-
GC2402 Study Site 105
RECRUITINGMiami, Florida, 33067, United States
Contact Email: •••••@•••••
-
GC2402 Study Site 106
RECRUITINGSherman, Texas, 75092, United States
Contact Email: •••••@•••••
-
GC2402 Study Site 109
RECRUITINGCoral Springs, Florida, 33155, United States
Contact Email: •••••@•••••
-
GC2402 Study Site 110
RECRUITINGNew York, New York, 10003, United States
Contact Email: •••••@•••••
-
GC2402 Study Site 111
RECRUITINGCordova, Tennessee, 38018, United States
Contact Email: •••••@•••••